218 related articles for article (PubMed ID: 31217827)
1. Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma.
Riccardo F; Tarone L; Iussich S; Giacobino D; Arigoni M; Sammartano F; Morello E; Martano M; Gattino F; Maria R; Ferrone S; Buracco P; Cavallo F
Ther Adv Med Oncol; 2019; 11():1758835919855491. PubMed ID: 31217827
[TBL] [Abstract][Full Text] [Related]
2. A chimeric human/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma.
Tarone L; Giacobino D; Camerino M; Maniscalco L; Iussich S; Parisi L; Giovannini G; Dentini A; Bolli E; Quaglino E; Merighi IF; Morello E; Buracco P; Riccardo F; Cavallo F
Mol Ther; 2023 Aug; 31(8):2342-2359. PubMed ID: 37312451
[TBL] [Abstract][Full Text] [Related]
3. CSPG4: a prototype oncoantigen for translational immunotherapy studies.
Rolih V; Barutello G; Iussich S; De Maria R; Quaglino E; Buracco P; Cavallo F; Riccardo F
J Transl Med; 2017 Jul; 15(1):151. PubMed ID: 28668095
[TBL] [Abstract][Full Text] [Related]
4. Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.
Riccardo F; Tarone L; Camerino M; Giacobino D; Iussich S; Barutello G; Arigoni M; Conti L; Bolli E; Quaglino E; Merighi IF; Morello E; Dentini A; Ferrone S; Buracco P; Cavallo F
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580930
[TBL] [Abstract][Full Text] [Related]
5. Improving Osteosarcoma Treatment: Comparative Oncology in Action.
Tarone L; Mareschi K; Tirtei E; Giacobino D; Camerino M; Buracco P; Morello E; Cavallo F; Riccardo F
Life (Basel); 2022 Dec; 12(12):. PubMed ID: 36556464
[TBL] [Abstract][Full Text] [Related]
6. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.
Beard RE; Zheng Z; Lagisetty KH; Burns WR; Tran E; Hewitt SM; Abate-Daga D; Rosati SF; Fine HA; Ferrone S; Rosenberg SA; Morgan RA
J Immunother Cancer; 2014; 2():25. PubMed ID: 25197555
[TBL] [Abstract][Full Text] [Related]
7. Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma.
Mayayo SL; Prestigio S; Maniscalco L; Rosa G; Aricò A; Maria R; Cavallo F; Ferrone S; Buracco P; Iussich S
Vet J; 2011 Nov; 190(2):e26-e30. PubMed ID: 21482159
[TBL] [Abstract][Full Text] [Related]
8. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.
Kurokawa T; Imai K
Proc Jpn Acad Ser B Phys Biol Sci; 2024; 100(5):293-308. PubMed ID: 38735753
[TBL] [Abstract][Full Text] [Related]
9. CSPG4-targeting CAR-macrophages inhibit melanoma growth.
Greiner D; Xue Q; Waddell TQ; Kurudza E; Belote RL; Dotti G; Judson-Torres RL; Reeves MQ; Cheshier SH; Roh-Johnson M
bioRxiv; 2024 Jun; ():. PubMed ID: 38895447
[TBL] [Abstract][Full Text] [Related]
10. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of canonical Hedgehog signaling pathway inhibition in canine osteosarcoma.
Baldanza VE; Rogic A; Yan W; Levine CB; Levine RA; Miller AD; McCleary-Wheeler AL
PLoS One; 2020; 15(4):e0231762. PubMed ID: 32348319
[TBL] [Abstract][Full Text] [Related]
12. Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.
Ilieva KM; Cheung A; Mele S; Chiaruttini G; Crescioli S; Griffin M; Nakamura M; Spicer JF; Tsoka S; Lacy KE; Tutt ANJ; Karagiannis SN
Front Immunol; 2017; 8():1911. PubMed ID: 29375561
[TBL] [Abstract][Full Text] [Related]
13. Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.
Nota SPFT; Osei-Hwedieh DO; Drum DL; Wang X; Sabbatino F; Ferrone S; Schwab JH
Front Oncol; 2022; 12():939166. PubMed ID: 36110930
[TBL] [Abstract][Full Text] [Related]
14. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response.
Boudin L; de Nonneville A; Finetti P; Mescam L; Le Cesne A; Italiano A; Blay JY; Birnbaum D; Mamessier E; Bertucci F
J Transl Med; 2022 Oct; 20(1):464. PubMed ID: 36221119
[TBL] [Abstract][Full Text] [Related]
15. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.
Geldres C; Savoldo B; Hoyos V; Caruana I; Zhang M; Yvon E; Del Vecchio M; Creighton CJ; Ittmann M; Ferrone S; Dotti G
Clin Cancer Res; 2014 Feb; 20(4):962-71. PubMed ID: 24334762
[TBL] [Abstract][Full Text] [Related]
16. Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research.
Tarone L; Giacobino D; Camerino M; Ferrone S; Buracco P; Cavallo F; Riccardo F
Front Vet Sci; 2022; 9():803093. PubMed ID: 35224082
[TBL] [Abstract][Full Text] [Related]
17. Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
Hsu SC; Nadesan P; Puviindran V; Stallcup WB; Kirsch DG; Alman BA
J Biol Chem; 2018 Feb; 293(7):2466-2475. PubMed ID: 29196603
[TBL] [Abstract][Full Text] [Related]
18. HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors.
Dailey DD; Anfinsen KP; Pfaff LE; Ehrhart EJ; Charles JB; Bønsdorff TB; Thamm DH; Powers BE; Jonasdottir TJ; Duval DL
BMC Vet Res; 2013 Jul; 9():130. PubMed ID: 23816051
[TBL] [Abstract][Full Text] [Related]
19. CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL.
Jordaan S; Chetty S; Mungra N; Koopmans I; van Bommel PE; Helfrich W; Barth S
Biomedicines; 2017 Jun; 5(3):. PubMed ID: 28657611
[TBL] [Abstract][Full Text] [Related]
20. Characterization of STAT3 activation and expression in canine and human osteosarcoma.
Fossey SL; Liao AT; McCleese JK; Bear MD; Lin J; Li PK; Kisseberth WC; London CA
BMC Cancer; 2009 Mar; 9():81. PubMed ID: 19284568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
